Longest follow-up data reported for kite's tecartus® car t-cell therapy at ash 2024 reinforce durable efficacy and survival benefits

Santa monica, calif.--(business wire)--kite, a gilead company (nasdaq: gild), announced results today from four analyses that continue to demonstrate the durability of response of tecartus® (brexucabtagene autoleucel) in patients with relapsed/refractory mantle cell lymphoma (r/r mcl) and relapsed/refractory b-cell precursor acute lymphoblastic leukemia (r/r b-all) during the 66th american society of hematology (ash) annual meeting and exposition. the data presented include an oral presentation.
CAR Ratings Summary
CAR Quant Ranking